News | February 07, 2014

Corus CAD Gene Expression Test Correlates With Plaque Burden, Obstructive Coronary Artery Disease

Study results validated by CT angiography

February 7, 2014 — CardioDx Inc. is a molecular diagnostics company specializing in cardiovascular genomics. It published an analysis demonstrating that the Corus CAD gene expression score is significantly associated with plaque burden and luminal stenosis. The holds true in symptomatic patients being evaluated for obstructive coronary artery disease (CAD), as measured by CT-angiography. The study, "A Peripheral Blood Gene Expression Score is Associated with Atherosclerotic Plaque Burden and Stenosis by Cardiovascular CT-Angiography," appears online in the journal Atherosclerosis.
 
"Our understanding of the relationship between peripheral blood gene expression, as measured by the Corus CAD gene expression score, and plaque composition and stenosis determined by CT-angiography continues to grow," said Steven Rosenberg, Ph.D., senior author and a member of CardioDx's Scientific Advisory Board. "These findings are important as they show that the Corus CAD score, which provides an estimate of a patient's likelihood of obstructive CAD, offers additional information related to disease burden that is useful in the diagnostic evaluation of the patient."
 
In this subgroup analysis, which included 610 patients from the PREDICT and COMPASS studies, the Corus CAD gene expression score was significantly associated with plaque burden (p < 0.001) and luminal stenosis (p < 0.01) as measured by CT-angiography. Additionally, the Corus CAD gene expression score was a stronger predictor of stenosis, as compared to the Diamond-Forrester clinical classification. Furthermore, an increasingly higher Corus CAD gene expression score was associated with increasing maximal stenosis, as determined by CT-angiography (p < 0.001).
 
Corus CAD is a blood test that can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD. 
 
For more information: www.cardiodx.com

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init